Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
50 Biggest Movers From Yesterday
Gainers
Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target.
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
Atara Biotherapeutics And Pierre Fabre Enter Strategic Collaboration To Commercialize Tabelecleucel; Atara To Receive Upfront Payment Of $45M, And Up To ~$320M In Total Milestones
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for
Atar Biotherapeutics Reports European Medicines Agency Grant For Co.’s Accelerated Assessment Of tab-cel For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Designation recognizes therapeutic innovation and potential to address significant unmet patient need
Atara on track to submit MAA in November 2021
Phase 3 ALLELE study analysis supporting tab-cel MAA to be presented
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
Atara Biotherapeutics Q2 EPS $(0.91) Misses $(0.89) Estimate, Sales $3.87M Beat $3.84M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.89) by 2.25 percent. This is a 20.18 percent increase over losses of $(1.14) per share
Understanding Atara Biotherapeutics’s Unusual Options Activity
On Monday, shares of Atara Biotherapeutics (NASDAQ:ATRA) saw unusual options activity. After the option alert, the stock price moved down to $12.48.